Pharma Focus Asia

Amgen Opens New Biomanufacturing Plant in North Carolina

Introduction:

Amgen announces plans for the construction of new manufacturing facility. The new plant will be dedicated in manufacturing medicines to treat serious illnesses such as cancer and heart disease.

Features:

The new manufacturing facility will be added to the existing robust biomanufacturing ecosystem. It ensures to produce wide range of medicines to patients by making use of new technologies to maximize efficiency and quality.

The new facility will meet the exacting environmental standards, reduces water usage by 40 percent and waste by 75 percent and becoming carbon neutrality by 2027. Moreover, the plant evolves as a major hub for biopharmaceutical innovation.

Currently it has manufacturing facilities in California, Ireland, Netherlands, Ohio, Puerto Rico, Rhode Island and Singapore.

The construction of the new facility is expected to be completed and fully operational by 2025.

The site already consists of 24,000 employees worldwide and the new facility is expected to add an additional 350 high-quality new jobs.

Specifications:

NameAmgen
TypeNew Construction
Year2022
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference